Clinical Studies for ES-SCLC

Exploring a potential new approach for extensive-stage small-cell lung cancer.

About the trial:

These studies are evaluating an investigational immunotherapy drug in patients with extensive-stage small-cell lung cancer (ES-SCLC). The goal is to determine whether adding this drug can safely improve cancer control and survival in ES-SCLC.

Even with current therapies, people with ES-SCLC typically have a median survival of 7 to 11 months.¹

Because many SCLC cases do not respond long-term to chemotherapy alone, adding potential new therapies could help engage the immune system to fight back.²

Take the survey

You might be eligible if you:

Are over 18 years old

Have been diagnosed with ES-SCLC

Are considering your treatment options

Are interested in participating in a clinical trial

Take a quick survey today to see if you prequalify.

Take the survey

1. https://www.medicalnewstoday.com/articles/prognosis-of-extensive-small-cell-lung-cancer
2. https://emedicine.medscape.com/article/280104-overview

You might be eligible if you:

Take the Survey